We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+26.71%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$624M
AUM Growth
+$131M
Cap. Flow
+$40.1M
Cap. Flow %
6.42%
Top 10 Hldgs %
81.94%
Holding
58
New
13
Increased
11
Reduced
7
Closed
13
Avg Time Held
0.9 years
Top 10 Avg Time Held
0.7 years
Top 20 Avg Time Held
0.6 years

Top Buys

Rank Stock Value
1
MOBI icon
Mobia Medical
MOBI
+$10.3M
2
SENS icon
Senseonics Holdings Inc
SENS
+$10.3M
3
CGON icon
CG Oncology
CGON
+$7.19M
4
ELVN icon
Enliven Therapeutics
ELVN
+$6.37M
5
JBIO icon
Jade Biosciences
JBIO
+$6.26M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$8.33M
2
VIR icon
Vir Biotechnology
VIR
+$4.1M
3
MDT icon
Medtronic
MDT
+$2.42M
4
CNC icon
Centene
CNC
+$2.29M
5
NTRA icon
Natera
NTRA
+$1.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Consumer Staples 0.17%
3 Consumer Discretionary 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ALMR icon
26
Alamar Biosciences
ALMR
$1.79B
$2.98M 0.48%
+110,000
New +$2.49M
2026 Q2
0 quarters
CNTX icon
27
Context Therapeutics
CNTX
$21.9M
$2.77M 0.44%
4,998,267
– –
2024 Q2
8 quarters
GILD icon
28
Gilead Sciences
GILD
$194B
$2.53M 0.4%
20,000
– –
2026 Q1
1 quarter
CRL icon
29
Charles River Laboratories
CRL
$14.6B
$2.27M 0.36%
+10,000
New +$1.78M
2026 Q2
0 quarters
PHAT icon
30
Phathom Pharmaceuticals
PHAT
$589M
$2.17M 0.35%
200,000
-49,390
-20% -$564K
2021 Q4
18 quarters
AVLN icon
31
Avalyn Pharma
AVLN
$1.1B
$1.98M 0.32%
+60,000
New +$1.73M
2026 Q2
0 quarters
KLRA icon
32
Kailera Therapeutics
KLRA
$1.5B
$1.76M 0.28%
+80,000
New +$1.76M
2026 Q2
0 quarters
GMAB icon
33
Genmab
GMAB
$23.3B
$1.37M 0.22%
50,000
– –
2025 Q2
4 quarters
NTLA icon
34
Intellia Therapeutics
NTLA
$1.59B
$1.27M 0.2%
75,000
– –
2026 Q1
1 quarter
CRVS icon
35
Corvus Pharmaceuticals
CRVS
$817M
$1.2M 0.19%
80,000
-35,000
-30% -$486K
2026 Q1
1 quarter
ODD icon
36
ODDITY Tech
ODD
$1.06B
$1.06M 0.17%
70,000
– –
2026 Q1
1 quarter
SCYX icon
37
SCYNEXIS
SCYX
$37.8M
$1.06M 0.17%
260,206
-2
-0% -$12
2023 Q2
12 quarters
EVMN icon
38
Evommune Inc
EVMN
$198M
$997K 0.16%
+75,000
New +$1.74M
2026 Q2
0 quarters
ABT icon
39
Abbott
ABT
$182B
$907K 0.15%
+10,000
New +$913K
2026 Q2
0 quarters
BBIO icon
40
BridgeBio Pharma
BBIO
$13B
$745K 0.12%
+10,000
New +$700K
2026 Q2
0 quarters
PTON icon
41
Peloton Interactive
PTON
$2.36B
$591K 0.09%
100,000
-100,000
-50% -$539K
2026 Q1
1 quarter
LEGN icon
42
Legend Biotech
LEGN
$3.7B
$433K 0.07%
+15,000
New +$405K
2026 Q2
0 quarters
BBOT icon
43
BridgeBio Oncology
BBOT
$233M
$334K 0.05%
43,853
– –
2026 Q1
1 quarter
SVRA icon
44
Savara
SVRA
$943M
$308K 0.05%
+50,000
New +$268K
2026 Q2
0 quarters
TRVI icon
45
Trevi Therapeutics
TRVI
$1.7B
$124K 0.02%
6,660
– –
2026 Q1
1 quarter
ABUS icon
46
Arbutus Biopharma
ABUS
$840M
– –
-125,000
Closed -$563K –
ABVX icon
47
Abivax
ABVX
$7.8B
– –
-10,000
Closed -$1.11M –
ACAD icon
48
Acadia Pharmaceuticals
ACAD
$3.34B
– –
-12,967
Closed -$289K –
CNC icon
49
Centene
CNC
$34.3B
– –
-70,000
Closed -$2.29M –
CORT icon
50
Corcept Therapeutics
CORT
$12B
– –
-30,000
Closed -$1.21M –
1
2
3

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
FGA
Fortis Group Advisors Westwood, New Jersey $626M AUM 33.6% 1-Year Est. Return
BVC
Bright Valley Capital Hong Kong $626M AUM 199.29% 1-Year Est. Return

Avidity Partners Management's Q2 2026 Portfolio in Review

As of Q2 2026, Avidity Partners Management held 58 positions worth $624M, up 26% from $494M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Avidity Partners Management deployed $40.1M of net new capital in Q2 2026, opening 13 new positions and adding to 11 existing holdings. Its largest new stake was Mobia Medical: 798,282 shares worth $10.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Teva Pharmaceutical Industries Limited, an estimated $8.33M trimmed.

  • Avidity Partners Management's largest Q2 2026 buy was Mobia Medical: 798,282 shares worth $10.7M.
  • Avidity Partners Management added most to CG Oncology in Q2 2026, an estimated $7.19M increase.
  • Avidity Partners Management's biggest Q2 2026 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $8.33M.
  • Avidity Partners Management fully exited Centene in Q2 2026, selling an estimated $2.29M.
  • Avidity Partners Management's ten largest holdings make up 82% of its $624M portfolio in Q2 2026.
  • Avidity Partners Management opened 13 new positions and closed 13 in Q2 2026.
  • Avidity Partners Management's portfolio value rose 26% quarter-over-quarter to $624M.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.